Search

Your search keyword '"Rossi, Maria Teresa"' showing total 115 results
Start Over Author "Rossi, Maria Teresa"
115 results on '"Rossi, Maria Teresa"'

1. Towards Model-Driven Dashboard Generation for Systems-of-Systems

Author

Rossi, Maria Teresa, Tundo, Alessandro, and Mariani, Leonardo

Subjects
Computer Science - Software Engineering
Abstract

Configuring and evolving dashboards in complex and large-scale Systems-of-Systems (SoS) can be an expensive and cumbersome task due to the many Key Performance Indicators (KPIs) that are usually collected and have to be arranged in a number of visualizations. Unfortunately, setting up dashboards is still a largely manual and error-prone task requiring extensive human intervention. This short paper describes emerging results about the definition of a model-driven technology-agnostic approach that can automatically transform a simple list of KPIs into a dashboard model, and then translate the model into an actual dashboard for a target dashboard technology. Dashboard customization can be efficiently obtained by solely modifying the abstract model representation, freeing operators from expensive interactions with actual dashboards.

Published
2024
Full Text
View/download PDF

2. Supporting Early-Safety Analysis of IoT Systems by Exploiting Testing Techniques

Author

Clerissi, Diego, Di Rocco, Juri, Di Ruscio, Davide, Di Sipio, Claudio, Ihirwe, Felicien, Mariani, Leonardo, Micucci, Daniela, Rossi, Maria Teresa, and Rubei, Riccardo

Subjects
Computer Science - Software Engineering
Abstract

IoT systems complexity and susceptibility to failures pose significant challenges in ensuring their reliable operation Failures can be internally generated or caused by external factors impacting both the systems correctness and its surrounding environment To investigate these complexities various modeling approaches have been proposed to raise the level of abstraction facilitating automation and analysis FailureLogic Analysis FLA is a technique that helps predict potential failure scenarios by defining how a components failure logic behaves and spreads throughout the system However manually specifying FLA rules can be arduous and errorprone leading to incomplete or inaccurate specifications In this paper we propose adopting testing methodologies to improve the completeness and correctness of these rules How failures may propagate within an IoT system can be observed by systematically injecting failures while running test cases to collect evidence useful to add complete and refine FLA rules

Published
2023

3. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Author

Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, Fernández-Orland, Almudena, Warren, Richard B, Agner, Tove, Schuttelaar, Marie L A, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, and Strange Vest, Natacha

Published
2024
Full Text
View/download PDF

6. Weaving Open Services with Runtime Models for Continuous Smart Cities KPIs Assessment

Author

De Sanctis, Martina, Iovino, Ludovico, Rossi, Maria Teresa, Wimmer, Manuel, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Hacid, Hakim, editor, Kao, Odej, editor, Mecella, Massimo, editor, Moha, Naouel, editor, and Paik, Hye-young, editor

Published
2021
Full Text
View/download PDF

7. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Author

Shah, Aadarsh, Barea, Alberto, Romero-Maté, Alberto, Singapore, Alekya, Paolino, Alexandra, Mwale, Alice, Morales Callaghan, Ana Maria, Martinez, Ana, DeCrescenzo, Andrew, Pink, Andrew E., Jones, Ann, Sergeant, Ann, Essex, Annette, Bewley, Anthony, Makrygeorgou, Areti, van Huizen, Astrid, Pérez-Suárez, Beatriz, Farida, Benhadou, Claréus, Birgitta Wilson, Prims, Carla Tubau, Davis, Carrie, Quinlan, Catherine, Maybury, Catriona, Cesar, Gonzalez A., Barclay, Charlotte, Greco, Claudio, Brassard, Danielle, Cummings, Deanna, Kolli, Deepti, Descamps, Vincent, Genao, Diana Ruiz, Carras, Efrossini, Hawryluk, Elena, Martínez-García, Eliseo, Klujszo, Elzbieta, Dwyer, Emily, Toni, Emmanuel, Sonkoly, Enikö, Loayza, Enrique, Daudén, Esteban, Valenzuela, Fernando, Popov, Georgi, King, Georgie, Celine, Girard, Aparicio, Gloria, Johnston, Graham A., Cardozo, Gustavo Anibal, Pearson, Ian, Yanguas, Ignacio, Weisman, Jamie, Carolan, Jennifer E., Hughes, Jenny, Ortiz-Salvador, Jose-Maria, Carrascosa, Jose-Manuel, Schwartz, Joseph J., Jackson, Karina, Kerisit, Kathryn G., Wu, Keith, Asfour, Leila, de Graaf, Leontien, Lesort, Cécile, Meuleman, Lieve, Eidsmo, Liv, Skov, Lone, Gribben, Lorraine, Rustin, Malcolm, Velasco, Manel, Panchal, Manisha, Lakhan, Manpreet, Franco, Manuel D., Svensson, Marie-Louise, Vandaele, Mark, Marovt, Maruska, Zargari, Omid, De Caso, Pablo, Varela, Paulo, Jenkin, Peter, Phan, Céline, Hampton, Philip, Goldsmith, Portia, Bak, Rachel, Speeckaert, Reinhart, Romiti, Ricardo, Woolf, Richard, Mercado-Seda, Rogelio, Khatun, Rohima, Ceovic, Romana, Taberner, Rosa, Cohen, Russell W., Stefanescu, Simina, Kirk, Sarah, Reeken, Saskia, Ayob, Shanti, Pérez-Barrio, Silvia, Piaserico, Stefano, Hoey, Susannah, Torres, Tiago, Talme, Toomas, Desai, Trupti V., van Geest, Adrienne J., King, Victoria, Di Lernia, Vito, Koreja, Zahira, Hasab, Vito Zeeshaan, Mahil, Satveer K., Dand, Nick, Mason, Kayleigh J., Yiu, Zenas Z.N., Tsakok, Teresa, Meynell, Freya, Coker, Bola, McAteer, Helen, Moorhead, Lucy, Mackenzie, Teena, Rossi, Maria Teresa, Rivera, Raquel, Mahe, Emmanuel, Carugno, Andrea, Magnano, Michela, Rech, Giulia, Balogh, Esther A., Feldman, Steven R., De La Cruz, Claudia, Choon, Siew Eng, Naldi, Luigi, Lambert, Jo, Spuls, Phyllis, Jullien, Denis, Bachelez, Hervé, McMahon, Devon E., Freeman, Esther E., Gisondi, Paolo, Puig, Luis, Warren, Richard B., Di Meglio, Paola, Langan, Sinéad M., Capon, Francesca, Griffiths, Christopher E.M., Barker, Jonathan N., and Smith, Catherine H.

Published
2021
Full Text
View/download PDF

8. A Flexible Architecture for Key Performance Indicators Assessment in Smart Cities

Author

De Sanctis, Martina, Iovino, Ludovico, Rossi, Maria Teresa, Wimmer, Manuel, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Jansen, Anton, editor, Malavolta, Ivano, editor, Muccini, Henry, editor, Ozkaya, Ipek, editor, and Zimmermann, Olaf, editor

Published
2020
Full Text
View/download PDF

9. Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, and Peris, Ketty

Published
2021
Full Text
View/download PDF

10. Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, and Peris, Ketty

Published
2022
Full Text
View/download PDF

11. Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study

Author

Guicciardi, Federica, Atzori, Laura, Marzano, Angelo Valerio, Tavecchio, Simona, Girolomoni, Giampiero, Colato, Chiara, Villani, Axel Patrice, Kanitakis, Jean, Mitteldorf, Christina, Satta, Rosanna, Cribier, Bernard, Gusdorf, Laurence, Rossi, Maria Teresa, Calzavara-Pinton, Piergiacomo, Bielsa, Isabel, Fernandez-Figueras, Maria Teresa, Kempf, Werner, Filosa, Giorgio, Pilloni, Luca, and Rongioletti, Franco

Published
2019
Full Text
View/download PDF

12. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Author

Bissonnette, Robert, Warren, Richard B, Pinter, Andreas, Agner, Tove, Gooderham, Melinda, Schuttelaar, Marie L A, Crépy, Marie-Noëlle, Stingeni, Luca, Serra-Baldrich, Esther, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, Strange Vest, Natacha, Schliemann, Sibylle, Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, and Fernández-Orland, Almudena

Abstract

Chronic hand eczema is a fluctuating, inflammatory, pruritic, often painful disease of hands and wrists that strongly impacts quality of life and occupational capabilities of patients. The aim of phase 3 DELTA 1 and DELTA 2 was to assess the efficacy and safety of twice-daily applications of the topical pan-Janus kinase inhibitor delgocitinib cream 20 mg/g versus cream vehicle in adults with moderate to severe chronic hand eczema.

Published
2024
Full Text
View/download PDF

17. Marine Data Observability using KPIS: An MDSE Approach

Author

Lima, K, Iovino, L, Rossi, M, Heldal, R, Oyetoyan, T, De Sanctis, M, Lima, Keila, Iovino, Ludovico, Rossi, Maria Teresa, Heldal, Rogardt, Oyetoyan, Tosin Daniel, De Sanctis, Martina, Lima, K, Iovino, L, Rossi, M, Heldal, R, Oyetoyan, T, De Sanctis, M, Lima, Keila, Iovino, Ludovico, Rossi, Maria Teresa, Heldal, Rogardt, Oyetoyan, Tosin Daniel, and De Sanctis, Martina

Abstract

The 2023 climate change report states that the current temperature rise has led to recurring and hazardous weather events, devastating communities and the planet. Ocean observation systems and marine data generated by them are crucial for predicting these extreme events, understanding the ecosystem states, and regulating marine industries. Many regional and global initiatives have been supporting the collection and sharing of more data, filling gaps in ocean observation. However, some challenges can impact the quality of marine data at different points of data delivery pipelines: from acquisition and transmission at the Internet-of-Underwater-Things (IoUT) level up to storage and sharing. IoUT devices can have challenges due to limited battery, rough underwater terrain, error-prone wireless underwater communication, or low communication bandwidth to the cloud. Thus, mechanisms must be put in place to allow monitoring of data quality throughout the delivery pipeline, to optimize the usage of data and improve decision-making based on the data. This study explores observation of marine data quality on a data platform using Key Performance Indicators (KPIs). We have created a model of the platform and specified KPIs. Both are fulfilled by platform-collected data quality metrics, with the purpose to infer the state of the data in the platform over different periods. Our results show that the model-based implementation is able to function as a semantic translator between a metric monitoring toolkit and the platform objectives, integrating it into an observable subsystem for the overall middleware data platform.

Published
2023

18. Photodynamic Therapy

Author

Sala, Raffaella, Rossi, Maria Teresa, Calzavara-Pinton, Piergiacomo, Giordano, Antonio, Series editor, Baldi, Alfonso, editor, Pasquali, Paola, editor, and Spugnini, Enrico P, editor

Published
2014
Full Text
View/download PDF

20. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study

Author

Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iris, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study group, Balestri R, Bernardini N, Belloni Fortini A, Burlando M, Caldarola G, Campione E, Cattaneo A, Dapavo P, Dastoli S, De Simone C, Di Nuzzo S, Diotallevi F, Fierro MT, Franchi C, Esposito M, Foti C, Gambini DM, Gambardella A, Girolomoni G, Giunta A, Guarneri C, Gualdi G, Hansel K, Megna M, Mugheddu C, Musumeci ML, Patrizi A, Pellacani G, Richetta AG, Rosi E, Sacchelli L, Tiberio R, Tilotta G, Trovato E, Venturini M, Vezzoni R, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo', S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study, Group, Balestri, R, Bernardini, N, Belloni Fortini, A, Burlando, M, Caldarola, G, Campione, E, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, Mt, Franchi, C, Esposito, M, Foti, C, Gambini, Dm, Gambardella, A, Girolomoni, G, Giunta, A, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, Ml, Patrizi, A, Pellacani, G, Richetta, Ag, Rosi, E, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Venturini, M, Vezzoni, R, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Piaserico S., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Rossi M.T., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo' S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., and Peris K.

Subjects
0301 basic medicine, Male, Clinical Biochemistry, Disease, Cohort Studies, 0302 clinical medicine, Drug Discovery, Receptors, 80 and over, Medicine, Aged, 80 and over, education.field_of_study, Incidence (epidemiology), Incidence, Interleukin-17, psoriasis, Middle Aged, dermatology, sars-CoV-2, Italy, biological therapy, 030220 oncology & carcinogenesis, Cohort, Biological Product, COVID-19, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Adult, Aged, Biological Products, Biological Therapy, Chronic Disease, Humans, Pandemics, Psoriasis, Receptors, Interleukin, Risk Assessment, Tumor Necrosis Factor-alpha, Young Adult, Cohort study, Human, medicine.medical_specialty, Population, 03 medical and health sciences, Settore MED/35, Internal medicine, education, Pharmacology, Psoriasi, Pandemic, business.industry, Biological product, Interleukin, medicine.disease, Clinical trial, 030104 developmental biology, SARS-CoV-2, Cohort Studie, business
Abstract

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021

21. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author

Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Caldarola, Giacomo, Silvaggio, Dionisio, Dattola, Annunziata, Napolitano, Maddalena, Ferrucci, Silvia Mariel, Dal Bello, Giacomo, Bianchelli, Tommaso, Rovati, Chiara, Pigliacelli, Flavia, Ortoncelli, Michela, Hansel, Katharina, Calabrese, Giulia, Loi, Camilla, Iannone, Michela, Veronese, Federica, Romita, Paolo, Tronconi, Greta, Caroppo, Francesca, Tilotta, Giovanna, Sernicola, Alvise, Esposito, Maria, Raponi, Francesca, Gualdi, Giulio, Rech, Giulia, Musumeci, Maria Letizia, Nisticò, Steven Paul, Campitiello, Alessio, Bonzano, Laura, Piras, Viviana, Chiricozzi, A., Talamonti, M., De Simone, C., Galluzzo, M., Gori, N., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Di Nardo, L., Guarneri, F., Peris, K., Caldarola, G., Silvaggio, D., Dattola, A., Napolitano, M., Ferrucci, S. M., Dal Bello, G., Bianchelli, T., Rovati, C., Pigliacelli, F., Ortoncelli, M., Hansel, K., Calabrese, G., Loi, C., Iannone, M., Veronese, F., Romita, P., Tronconi, G., Caroppo, F., Tilotta, G., Sernicola, A., Esposito, M., Raponi, F., Gualdi, G., Rech, G., Musumeci, M. L., Nistico, S. P., Campitiello, A., Bonzano, L., Piras, V., Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Caldarola, Giacomo, Silvaggio, Dionisio, Dattola, Annunziata, Napolitano, Maddalena, Ferrucci, Silvia Mariel, Dal Bello, Giacomo, Bianchelli, Tommaso, Rovati, Chiara, Pigliacelli, Flavia, Ortoncelli, Michela, Hansel, Katharina, Calabrese, Giulia, Loi, Camilla, Iannone, Michela, Veronese, Federica, Romita, Paolo, Tronconi, Greta, Caroppo, Francesca, Tilotta, Giovanna, Sernicola, Alvise, Esposito, Maria, Raponi, Francesca, Gualdi, Giulio, Rech, Giulia, Musumeci, Maria Letizia, Nisticò, Steven Paul, Campitiello, Alessio, Bonzano, Laura, Piras, Viviana, Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, and Piras, V

Subjects
Registrie, 0301 basic medicine, Dermatitis, Systemic therapy, 0302 clinical medicine, Pandemic, Immunology and Allergy, Medicine, Registries, atopic dermatitis, COVID, SARS‐ CoV, treatment, SARS-CoV, Atopic dermatitis, Dupilumab, Italy, Original Article, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human, atopic dermatiti, Adult, medicine.medical_specialty, Teledermatology, SARS‐CoV, atopic dermatitis, treatment, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Communicable Disease Control, Humans, Pandemics, SARS-CoV-2, COVID-19, Dermatitis, Atopic, Atopic, 03 medical and health sciences, Settore MED/35, Disease severity, Internal medicine, business.industry, medicine.disease, 030104 developmental biology, 030228 respiratory system, atopic dermatitis, COVID, SARS-CoV, business
Abstract

Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician‐ and patient‐reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS‐CoV‐2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID‐related death occurred. Conclusions Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab‐treated patients., Among 1831 studied AD patients, 86.1% were treated with dupilumab. Patients continuing therapy experienced a marked reduction of disease severity during pandemic. The causes of treatment interruption included: fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%), occurrence of comorbidities (5.9%), age above 60 years (5.2%), SARS‐CoV‐2 infection (2.8%), close contact with SARS‐CoV‐2‐positive subject (2.4%), other reasons, for example, inability to maintain drug supply, non‐medical/unspecified causes (58.7%).

Published
2021

29. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry Running title: AD management during COVID-19 pandemic

Author

Chiricozzi, Andrea, primary, Talamonti, Marina, additional, Simone, Clara De, additional, Galluzzo, Marco, additional, Gori, Niccolò, additional, Fabbrocini, Gabriella, additional, Marzano, Angelo Valerio, additional, Girolomoni, Giampiero, additional, Offidani, Annamaria, additional, Rossi, Maria Teresa, additional, Bianchi, Luca, additional, Cristaudo, Antonio, additional, Fierro, Maria Teresa, additional, Stingeni, Luca, additional, Pellacani, Giovanni, additional, Argenziano, Giuseppe, additional, Patrizi, Annalisa, additional, Pigatto, Paolo, additional, Romanelli, Marco, additional, Savoia, Paola, additional, Rubegni, Pietro, additional, Foti, Caterina, additional, Milanesi, Nicola, additional, Fortina, Anna Belloni, additional, Bongiorno, Maria Rita, additional, Grieco, Teresa, additional, Nuzzo, Sergio Di, additional, Fargnoli, Maria Concetta, additional, Carugno, Andrea, additional, Motolese, Alberico, additional, Rongioletti, Franco, additional, Amerio, Paolo, additional, Balestri, Riccardo, additional, Potenza, Concetta, additional, Micali, Giuseppe, additional, Patruno, Cataldo, additional, Zalaudek, Iris, additional, Lombardo, Maurizio, additional, Feliciani, Claudio, additional, Nardo, Lucia Di, additional, Guarneri, Fabrizio, additional, Peris, Ketty, additional, and Da-, Md ;, additional

Published
2021
Full Text
View/download PDF

30. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Author

Mahil, Satveer K., primary, Dand, Nick, additional, Mason, Kayleigh J., additional, Yiu, Zenas Z.N., additional, Tsakok, Teresa, additional, Meynell, Freya, additional, Coker, Bola, additional, McAteer, Helen, additional, Moorhead, Lucy, additional, Mackenzie, Teena, additional, Rossi, Maria Teresa, additional, Rivera, Raquel, additional, Mahe, Emmanuel, additional, Carugno, Andrea, additional, Magnano, Michela, additional, Rech, Giulia, additional, Balogh, Esther A., additional, Feldman, Steven R., additional, De La Cruz, Claudia, additional, Choon, Siew Eng, additional, Naldi, Luigi, additional, Lambert, Jo, additional, Spuls, Phyllis, additional, Jullien, Denis, additional, Bachelez, Hervé, additional, McMahon, Devon E., additional, Freeman, Esther E., additional, Gisondi, Paolo, additional, Puig, Luis, additional, Warren, Richard B., additional, Di Meglio, Paola, additional, Langan, Sinéad M., additional, Capon, Francesca, additional, Griffiths, Christopher E.M., additional, Barker, Jonathan N., additional, Smith, Catherine H., additional, Shah, Aadarsh, additional, Barea, Alberto, additional, Romero-Maté, Alberto, additional, Singapore, Alekya, additional, Paolino, Alexandra, additional, Mwale, Alice, additional, Morales Callaghan, Ana Maria, additional, Martinez, Ana, additional, DeCrescenzo, Andrew, additional, Pink, Andrew E., additional, Jones, Ann, additional, Sergeant, Ann, additional, Essex, Annette, additional, Bewley, Anthony, additional, Makrygeorgou, Areti, additional, van Huizen, Astrid, additional, Pérez-Suárez, Beatriz, additional, Farida, Benhadou, additional, Claréus, Birgitta Wilson, additional, Prims, Carla Tubau, additional, Davis, Carrie, additional, Quinlan, Catherine, additional, Maybury, Catriona, additional, Cesar, Gonzalez A., additional, Barclay, Charlotte, additional, Greco, Claudio, additional, Brassard, Danielle, additional, Cummings, Deanna, additional, Kolli, Deepti, additional, Descamps, Vincent, additional, Genao, Diana Ruiz, additional, Carras, Efrossini, additional, Hawryluk, Elena, additional, Martínez-García, Eliseo, additional, Klujszo, Elzbieta, additional, Dwyer, Emily, additional, Toni, Emmanuel, additional, Sonkoly, Enikö, additional, Loayza, Enrique, additional, Daudén, Esteban, additional, Valenzuela, Fernando, additional, Popov, Georgi, additional, King, Georgie, additional, Celine, Girard, additional, Aparicio, Gloria, additional, Johnston, Graham A., additional, Cardozo, Gustavo Anibal, additional, Pearson, Ian, additional, Yanguas, Ignacio, additional, Weisman, Jamie, additional, Carolan, Jennifer E., additional, Hughes, Jenny, additional, Ortiz-Salvador, Jose-Maria, additional, Carrascosa, Jose-Manuel, additional, Schwartz, Joseph J., additional, Jackson, Karina, additional, Kerisit, Kathryn G., additional, Wu, Keith, additional, Asfour, Leila, additional, de Graaf, Leontien, additional, Lesort, Cécile, additional, Meuleman, Lieve, additional, Eidsmo, Liv, additional, Skov, Lone, additional, Gribben, Lorraine, additional, Rustin, Malcolm, additional, Velasco, Manel, additional, Panchal, Manisha, additional, Lakhan, Manpreet, additional, Franco, Manuel D., additional, Svensson, Marie-Louise, additional, Vandaele, Mark, additional, Marovt, Maruska, additional, Zargari, Omid, additional, De Caso, Pablo, additional, Varela, Paulo, additional, Jenkin, Peter, additional, Phan, Céline, additional, Hampton, Philip, additional, Goldsmith, Portia, additional, Bak, Rachel, additional, Speeckaert, Reinhart, additional, Romiti, Ricardo, additional, Woolf, Richard, additional, Mercado-Seda, Rogelio, additional, Khatun, Rohima, additional, Ceovic, Romana, additional, Taberner, Rosa, additional, Cohen, Russell W., additional, Stefanescu, Simina, additional, Kirk, Sarah, additional, Reeken, Saskia, additional, Ayob, Shanti, additional, Pérez-Barrio, Silvia, additional, Piaserico, Stefano, additional, Hoey, Susannah, additional, Torres, Tiago, additional, Talme, Toomas, additional, Desai, Trupti V., additional, van Geest, Adrienne J., additional, King, Victoria, additional, Di Lernia, Vito, additional, Koreja, Zahira, additional, and Hasab, Vito Zeeshaan, additional

Published
2021
Full Text
View/download PDF

31. Polymorphous light eruption and benign summer light eruption in Italy

Author

Guarrera, Marcella, Cardo, Pasquale, Rebora, Alfredo Enrico, Schena, Donatella, Calzavara-Pinton, Piergiacomo, Venturini, Marina, Monfrecola, Giuseppe, Baldo, Antonello, Leone, Giovanni, Pacifico, Alessia, Pavesi, Alessandra, Ciambellotti, Aldo, Sala, Raffaella, Rossi, Maria Teresa, Di Costanzo, Luisa, and Fabbrocini, Gabriella

Published
2011
Full Text
View/download PDF

32. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry

Author

Chiricozzi, Andrea, primary, Talamonti, Marina, additional, Simone, Clara De, additional, Galluzzo, Marco, additional, Gori, Niccolò, additional, Fabbrocini, Gabriella, additional, Marzano, Angelo, additional, Girolomoni, Giampiero, additional, Offidani, Anna Maria, additional, Rossi, Maria Teresa, additional, Bianchi, Luca, additional, Cristaudo, Antonio, additional, Fierro, Maria Teresa, additional, Stingeni, Luca, additional, Pellacani, Giovanni, additional, Argenziano, Giovanni, additional, Patrizi, Annalisa, additional, Pigatto, Paolo, additional, Romanelli, Marco, additional, Savoia, Paola, additional, Rubegni, Pietro, additional, Foti, Caterina, additional, Milanesi, Nicola, additional, Fortina, Anna Belloni, additional, Bongiorno, Maria Rita, additional, Grieco, Teresa, additional, Nuzzo, Sergio Di, additional, Fargnoli, Maria Concetta, additional, Carugno, Andrea, additional, Motolese, Alberico, additional, Rongioletti, Franco, additional, Amerio, Paolo, additional, Balestri, Riccardo, additional, Potenza, Concetta, additional, Micali, Giuseppe, additional, Patruno, Cataldo, additional, Zalaudek, Iris, additional, Lombardo, Maurizio, additional, Feliciani, Claudio, additional, Guarneri, Fabrizio, additional, and Peris, Ketty, additional

Published
2020
Full Text
View/download PDF

33. Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy

Author

Ventura, Paolo, additional, Brancaleoni, Valentina, additional, Di Pierro, Elena, additional, Graziadei, Giovanna, additional, Macrì, Annelise, additional, Carmine Guida, Claudio, additional, Nicolli, Annamaria, additional, Rossi, Maria Teresa, additional, Granata, Francesca, additional, Fiorentino, Valeria., additional, Fustinoni, Silvia, additional, Sala, Raffella, additional, Pinton, Piergiacomo Calzavara, additional, Trevisan, Andrea, additional, Marchini, Stefano, additional, Cuoghi, Chiara, additional, Marcacci, Matteo, additional, Corradini, Elena, additional, Sorge, Fiammetta, additional, Aurizi, Caterina, additional, Savino, Maria Grazia, additional, Cappellini, Maria Domenica, additional, and Pietrangelo, Antonello, additional

Published
2020
Full Text
View/download PDF

35. Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study

Author

Bossi, Paolo, primary, Peris, Ketty, additional, Calzavara-Pinton, Piergiacomo, additional, Queirolo, Paola, additional, Alfieri, Salvatore, additional, Palla, Marco, additional, Rossi, Maria Teresa, additional, Spagnolo, Francesco, additional, Tambone, Sara, additional, Astolfi, Cinzia, additional, and Ascierto, Paolo A, additional

Published
2020
Full Text
View/download PDF

36. Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15-year experience

Author

Calzavara-Pinton, Piergiacomo, primary, Fabbrocini, Gabriella, additional, Girolomoni, Giampiero, additional, Matiucci, Alessandra, additional, Micali, Giuseppe, additional, Musumeci, Maria L., additional, Patruno, Cataldo, additional, Pellacani, Giovanni, additional, Rossi, Maria Teresa, additional, Castello, Michela, additional, and Stingeni, Luca, additional

Published
2020
Full Text
View/download PDF

39. Clinical and Spectrophotometric Evaluation of Skin Photoadaptation in Vitiligo Patients after a Short Cycle of NB-UVB Phototherapy.

Author

Arisi, Mariachiara, Rossi, Maria Teresa, Fusano, Marta, Gualini, Alessandra, Tomasi, Cesare, Moggio, Erica, Caravello, Simone, Calzavara-Pinton, Piergiacomo, Venturini, Marina, and Rossi, Maria Teresa

Abstract

Background: The phenomenon of photoadaptation to narrow-band ultraviolet B (NB-UVB) radiation has been previously described in vitiligo and has usually been clinically measured by the assessment of the minimal erythema dose (MED) after phototesting.Objectives: To assess the photoadaptive response in vitiligo and healthy skin after NB-UVB phototherapy not only clinically, but also by spectrophotometry.Materials and Methods: Fourteen patients affected by generalized vitiligo underwent NB-UVB phototherapy twice weekly for 12 weeks. Before and after phototherapy, a phototesting procedure was administered on vitiligo patches and adjacent healthy skin with a solar simulated radiation (SSR). Visual assessment of the MED took place after 24 h. A spectrophotometer was used to assess the a* value and the melanin index (MI*), as signs of skin erythema and pigmentation. The photoadaptation factor (MED-PF) and the a* photoadaptation factor (a*-PF) were calculated.Results: After NB-UVB phototherapy, both vitiligo and healthy skin showed an increase in MED and MI* values and a reduction of skin erythema compared to baseline (p < 0.05). MED-PF data showed a photoadaptation in 10 (71.4%) vitiligo lesions and in 12 (85.7%) healthy skin areas. The assessment of the a*-PF showed a negative mean percentage value in all affected and unaffected skin areas.Conclusions: A short cycle of NB-UVB phototherapy can induce photoadaptation in vitiligo by increasing the MED and reducing skin erythema after stimulation with SSR. This is most likely due to the physical filter function induced by ultraviolet radiation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. Sunlight-induced Painful Skin (Sun Pain): A New Differential Diagnosis in Photodermatology.

Author

CALZAVARA-PINTON, Piergiacomo, VENTURINI, Marina, ROVATI, Chiara, ARISI, Mariachiara, CALZAVARA-PINTON, Irene, RINALDI, Fabrizio, and ROSSI, Maria Teresa

Subjects
ULTRAVIOLET radiation, VISIBLE spectra, DIFFERENTIAL diagnosis, SKIN cancer, MENTAL depression, FIBROMYALGIA, PATIENTS' attitudes
Abstract

Photodermatoses are characterized by the development of skin eruptions following exposure to ultraviolet radiation or visible light. We report here the clinical findings and results of laboratory investigations and phototesting of 6 patients who experience debilitating and excruciating pain after sun exposure ("sun pain") in the absence of any skin eruption. Phototesting with sub-erythemal doses of ultraviolet A radiation triggered localized pain in 4 patients. At follow-up, 3 female patients were found to have developed fibromyalgia, 2 male patients experienced a major depressive disorder, and another male patient had a conversion disorder. One patient also developed allodynia to tactile stimuli and one developed allodynia to thermal and tactile stimuli. Psychiatric conditions should be taken into consideration in patients presenting with excruciating and debilitating pain on exposure to ultraviolet radiation, but with absence of skin eruption. Further research is needed to evaluate whether it represents a type of allodynia triggered by exposure to ultraviolet radiation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

41. Prevalence of Phototherapy in the Age of Biologics.

Author

Calzavara-Pinton, Piergiacomo, Zanca, Arianna, Arisi, Mariachiara, Rossi, Maria Teresa, Zane, Cristina, Venturini, Marina, Ortel, Bernhard, and Rossi, Maria Teresa

Subjects
PSORIASIS treatment, SKIN inflammation, PHOTOTHERAPY, BIOLOGICALS, SKIN disease diagnosis, BIOTHERAPY, DERMATOLOGIC agents, LONGITUDINAL method, PSORIASIS, MEDICAL radiology, ULTRAVIOLET radiation, SEVERITY of illness index, THERAPEUTICS
Abstract

Background: The prevalence of narrow-band ultraviolet B (NB-UVB) use in Europe for moderate and severe psoriasis is unknown, because national registries for psoriasis do not monitor this treatment.Objectives: To quantify the use of phototherapy, biologics or conventional treatments in psoriasis, in a setting where European Medicines Agency (EMA) eligibility criteria for biologics were strictly applied, and phototherapy was included among first-line treatments.Methods: We followed a cohort of 1,090 patients who were referred to the only centre entitled to prescribe biologics and phototherapy during a 5-year period.Results: The cumulative number of treatment cycles was: 1,047 with NB-UVB phototherapy, 650 with systemic treatments and 239 with biologics; 754 patients received at least 1 course of NB-UVB phototherapy, 422 at least 1 course with a systemic treatment and 137 with a biologic; 595 patients were treated only with phototherapy.Conclusions: Regular use of NB-UVB as first-line treatment for moderate and severe psoriasis and adherence to the EMA eligibility criteria for biologics led to a relatively restricted use of biologics. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

44. Dermoscopic, histological and immunohistochemical evaluation of cancerous features in acquired melanocytic nevi that have been repeatedly exposed to UVA or UVB

Author

Manganoni, Ausilia Maria, primary, Rossi, Maria Teresa, additional, Sala, Raffaella, additional, Venturini, Marina, additional, Sereni, Elena, additional, Ungari, Marco, additional, Marocolo, Daniela, additional, Lonardi, Silvia, additional, and Calzavara-Pinton, Piergiacomo, additional

Published
2011
Full Text
View/download PDF

47. Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study

Author

Angelo V. Marzano, Chiara Colato, Piergiacomo Calzavara-Pinton, Laurence Gusdorf, Luca Pilloni, Maria Teresa Rossi, Axel Patrice Villani, Simona Tavecchio, Werner Kempf, Federica Guicciardi, Bernard Cribier, Christina Mitteldorf, María Teresa Fernández-Figueras, Jean Kanitakis, Giampiero Girolomoni, Isabel Bielsa, Franco Rongioletti, Laura Atzori, Giorgio Filosa, Rosanna Satta, Guicciardi, Federica, Atzori, Laura, Marzano, Angelo Valerio, Tavecchio, Simona, Girolomoni, Giampiero, Colato, Chiara, Villani, Axel Patrice, Kanitakis, Jean, Mitteldorf, Christina, Satta, Rosanna, Cribier, Bernard, Gusdorf, Laurence, Rossi, Maria Teresa, Calzavara-Pinton, Piergiacomo, Bielsa, Isabel, Fernandez-Figueras, Maria Teresa, Kempf, Werner, Filosa, Giorgio, Pilloni, Luca, and Rongioletti, Franco

Subjects
Adult, Male, medicine.medical_specialty, Dermatology, Basement Membrane, Serology, Subacute cutaneous lupus erythematosus, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, histopathology study, medicine, Lupus Erythematosus, Cutaneous, Humans, Direct fluorescent antibody, Pathological, Retrospective Studies, Lupus erythematosus, business.industry, Age Factors, Mucins, Retrospective cohort study, Complement C3, Middle Aged, medicine.disease, 3. Good health, Europe, Exact test, Immunoglobulin M, drug-induced subacute lupus erythematosus, 030220 oncology & carcinogenesis, Antibodies, Antinuclear, subacute lupus erythematosus, Vasculitis, Leukocytoclastic, Cutaneous, Histopathology, Female, Drug Eruptions, business
Abstract

Background: Clinical and pathologic criteria to distinguish drug-induced subacute lupus erythematosus (DI-SCLE) from idiopathic (I-SCLE) are controversial. Objective: The aim of the survey was a retrospective analysis of a consistent number of iatrogenous and idiopathic SCLE cases, by means of clinical and histopathologic investigation. Methods: Eleven European university dermatology units collected all diagnosed cases from January 2000 to December 2016. Board-certified dermatopathologists reviewed the histopathologic specimens. Statistical analysis included Student t test, exact test of goodness-of-fit, Fisher's exact test, and the Cochran-Mantel-Haenszel test for repeated measures. Results: Out of 232 patients, 67 (29%) belonged to the DI-SCLE group. Patients with DI-SCLE were significantly older and reported more systemic symptoms than those with I-SCLE. No statistical differences were found for presentation pattern or serology, while histopathology showed a significant association of mucin deposition (P = .000083), direct immunofluorescence positivity for granular immunoglobulin M, and C3 deposits on the basement membrane zone (P = .0041) for I-SCLE and of leukocytoclastic vasculitis (P = .0018) for DI-SCLE. Limitations: This is a retrospective study. Conclusion: An integrated clinical and immunopathologic evaluation is useful to differentiate I-SCLE from DI-SCLE. Older age at onset and more frequent systemic symptoms characterize DI-SCLE. Mucin deposition and immunofluorescence findings are found in I-SCLE, and leukocytoclastic vasculitis is found in DI-SCLE.

Published
2019

48. Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

Author

Chiara Pagani, Serena Lavorgna, Maria Teresa Voso, Fausto Castagnetti, Giuseppina Ruggeri, Alessandro Turra, Camilla Zanaglio, Valeria Cancelli, Luca Franceschini, Erika Codarin, Domenico Russo, Giovanni Martinelli, Nicola Polverelli, Andrea Di Palma, Michele Baccarani, Mario Tiribelli, Federica Cattina, Bernardi Simona, Giuseppe Rossi, Gianantonio Rosti, Simona Soverini, Michele Malagola, Simone Perucca, Luigi Caimi, Claudia Venturi, Maria Teresa Bochicchio, Cristina Skert, Miriam Fogli, and Bernardi Simona, Andrea Di Palma, Federica Cattina, Simone Perucca, Michele Malagola, Mario Tiribelli, Erika Codarin, Maria Teresa Bochicchio, Giuseppina Ruggeri, Luca Franceschini, Valeria Cancelli, Fausto Castagnetti, Simona Soverini, Miriam Fogli, Claudia Venturi, Serena Lavorgna, Chiara Pagani, Cristina Skert, Camilla Zanaglio, Alessandro Turra, Nicola Polverelli, Luigi Caimi, Giuseppe Rossi, Maria Teresa Voso, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, Domenico Russo

Subjects
Oncology, medicine.medical_specialty, business.industry, Absolute quantification, Immunology, Cell Biology, Hematology, Biochemistry, Minimal residual disease, Bcr abl1, hemic and lymphatic diseases, Internal medicine, Medicine, Digital polymerase chain reaction, business, bcr-abl1, digital pcr, TFR
Abstract

Monitoring of BCR-ABL1 levels by quantitative PCR (qPCR) is essential for the management of CML patients treated with TKIs. Because of intrinsic limits, qPCR does not appear to be an optimal assay to select the best candidates to TKIs discontinuation. Up to 40% of CML patients treated with TKIs can achieve a Deep Molecular Response (DMR), but only 50% maintain a stable Treatment Free Remission (TFR) after therapy discontinuation. Digital PCR (dPCR), giving an absolute quantification of BCR-ABL1, is expected to be more sensitive and accurate than qPCR in the assessment of molecular MRD. dPCR performed on a QuantStudio 3D Digital PCR System (Life Technologies) by using a TaqMan-MGB probes targeting the BCR-ABL1 transcript was used to comparatively analyse 102 CML patients with Major (MR3.0 = 31 cases) or Deep (MR4.0= 33 cases; MR4.5 = 24 cases and MR5.0 = 14 cases) molecular response. Preliminary results showed that: a) ≥77% of deep responders (MR4.0, MR4.5 and MR5.0) fell under the value of 0.468 BCR-ABL1 copies/▢l indicated by the ROC analysis as the value below which the patients with lower levels of MRD might be dissected (spec.=71%, sens.=77%; AUC=0,79); b) BCR-ABL1 transcript levels were detectable by dPCR also in cases resulted undetectable by qPCR. In this study, we analysed the BCR-ABL1 transcript levels by dPCR in 207 samples related to 102 CML patients. Fourteen (14%) out of 102 CML patients discontinued the TKIs therapy. Among them, 3 patients (21%) lost DMR and all of them showed dPCR values > 0.468 BCR-ABL1 copies/▢l (previously described as cut-off for a deep MRD), while 11 (79%) maintained a stable DMR and 9 of them (82%) fell under the value of 0.468 BCR-ABL1 copies/▢l. These latter patients stratified in different DMR classes by qPCR and all had undetectable level of BCR-ABL1 by qPCR. In 149 out of 207, qPCR revealed DMR. They were: MR4.0= 59 samples; MR4.5= 61 cases; MR5.0 = 29 cases. One hundred twenty-five (84%) fell under the value of 0.468 BCR-ABL1 copies/▢l. A linear regression analysis in these samples did not show any correlation between BCR-ABL1 copies/▢l detected by qPCR with the ones detected by dPCR (R2 < 0.01). On the basis of our preliminary results, TFR seems to be correlated to the maintenance of dPCR values < 0.468 BCR-ABL1 copies/▢l. The concordance between qPCR and dPCR quantification in patients with DMR and with BCR-ABL1 copies/▢l value < 0.468 was poor. Patients with dPCR values < 0.468 BCR-ABL1 copies/▢l may have 75% of probability to maintain TFR status. These results suggest that dPCR may be more sensitive to detect the MRD and could be more useful for DMR monitoring and for dissecting the best candidate to discontinuation of therapy with TKIs. Disclosures Tiribelli: Ariad Pharmaceuticals: Consultancy, Speakers Bureau; Bristol-Myers Squibb: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau. Castagnetti:Bristol-Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; ARIAD Pharmaceuticals: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria. Soverini:Novartis: Consultancy; Ariad: Consultancy; Bristol-Myers Squibb: Consultancy. Rosti:Pfizer: Honoraria, Research Funding, Speakers Bureau; Roche: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria, Research Funding, Speakers Bureau; Incyte: Honoraria, Research Funding, Speakers Bureau; Novartis: Honoraria, Research Funding, Speakers Bureau. Martinelli:Roche: Consultancy; ARIAD: Consultancy; Pfizer: Consultancy, Speakers Bureau; Genentech: Consultancy; Amgen: Consultancy; MSD: Consultancy; Roche: Consultancy; ARIAD: Consultancy; Pfizer: Consultancy, Speakers Bureau; BMS: Speakers Bureau; Genentech: Consultancy; Amgen: Consultancy; Novartis: Speakers Bureau; MSD: Consultancy.

Published
2016

49. La partecipazione degli adolescenti: da articolo della Convenzione Onu a pratica quotidiana

Author

TAGLIAVENTI, MARIA TERESA, VALENTINA ROSSI, MARIA TERESA TAGLIAVENTI, CLAUDIA VALENTINI, and M. T. Tagliaventi

Subjects
PARTECIPAZIONE SOCIALE, LEGISLAZIONE, PRATICHE DI PROMOZIONE DELLA PARTECIPAZIONE, ADOLESCENTI, AMBITI DI VITA
Abstract

Il testo presenta una riflessione sui significati attribuibili al concetto di partecipazione sociale e analizza alcuni ambiti di espressione della partecipazione giovanile attraverso il dibattito in corso. C’è chi rileva infatti un forte calo nella pratica partecipativa delle giovani generazioni, e chi invece parla di nuove forme partecipative, che passano anche attraverso il web, e che si evidenziano in movimenti che trovano espressione in manifestazioni pubbliche non previste, più individualizzate e essenzialmente contingenti, come il partecipare ad un corteo, il firmare una petizione o la realizzazione di un flash mob. Nel testo viene anche presentata una rassegna critica dei principali impulsi dati a livello legislativo in questo ambito, a partire dalla Convenzione ONU del 1989 per arrivare alla proposta della legge 328 del 2000, e si conclude definendo alcune “buone” pratiche.

Published
2012

50. Per una lettura complessiva del progetto

Author

TAGLIAVENTI, MARIA TERESA, VALENTINA ROSSI, MARIA TERESA TAGLIAVENTI, CLAUDIA VALENTINI, and Maria Teresa, Tagliaventi

Subjects
PROGETTAZIONE PARTECIPATA, EVENTO SISMICO, ADOLESCENTI, L'AQUILA, SOCIALIZZAZIONE
Abstract

La premessa ha il compito di spiegare l’origine di un intervento di progettazione partecipata attuato a L’Aquila ad un anno dall’evento sismico del 2009. Il progetto, promosso dal Ministero del Lavoro e delle Politiche Sociali in collaborazione con il Centro Nazionale Documentazione e Analisi per l’Infanzia e l’Adolescenza, dalla Regione Abruzzo, dall’ANCI e dall’Ufficio Scolastico Regionale, è attuato in un contesto in cui il terremoto ha cambiato assetto alla città, prodotto ferite insanabili in tutte le persone e modificato profondamente il modo di socializzare, il sistema di vita quotidiano, le prospettive future di ogni cittadino, a partire dalle fasce più giovani della popolazione

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results